Preview

South Russian Journal of Therapeutic Practice

Advanced search

A case of development of membranous nephropathy against the background of atypical hemolytic-uremic syndrome activated as a result of acute respiratory viral infection

https://doi.org/10.21886/2712-8156-2023-4-4-101-106

Abstract

The article considers a clinical case of atypical hemolytic-uremic syndrome, which was the starting mechanism for the development of membranous nephropathy. Patient X. 23 years after acute respiratory viral infection, signs of nephrotic syndrome, arterial hypertension, and impaired kidney function appeared. Puncture nephrobiopsy was performed and the morphological picture corresponds to immunocomplex glomerulonephritis, most likely membranous nephropathy with the presence of segmental glomerulosclerosis, cellular half-moons. In parallel, the patient had verified signs of thrombotic microangiopathy in the form of microangiopathic anemia, thrombocytopenia, increased lactate dehydrogenase levels as a sign of cytolysis (primarily intravascular hemolysis). During the differential diagnosis, we stopped at the diagnosis of atypical hemolytic-uremic syndrome. The uniqueness of the described clinical case is that cases of glomerulonephritis against the background of atypical hemolytic-uremic syndrome are extremely rare, and membranous nephropathy is described for the first time.

About the Authors

M. M. Batiushin
Rostov State Medical University
Russian Federation

Mikhail M. Batiushin - Dr. Sci. (Med.), professor, Rostov State Medical University.

Rostov-on-Don



T. P. Beloborodova
Regional Clinical Hospital No. 2
Russian Federation

Tatiana P. Beloborodova.

Rostov-on-Don



V. L. Korobka
Rostov State Medical University
Russian Federation

Vyacheslav L. Korobka - Dr. Sci. (Med.), associate professor, Rostov State Medical University.

Rostov-on-Don



I. N. Nesterenko
Rostov State Medical University
Russian Federation

Irina N. Nesterenko.

Rostov-on-Don



E. A. Sinelnik
Regional Clinical Hospital No. 2
Russian Federation

Elena A. Sinelnik.

Rostov-on-Don



N. A. Bronovitskaya
Rostov State Medical University
Russian Federation

Natalia A. Bronovitskaya - Cand. Sci. (Med.), Rostov State Medical University.

Rostov-on-Don



N. B. Bondarenko
Rostov State Medical University
Russian Federation

Nikolay B. Bondarenko - Cand. Sci. (Med.), Rostov State Medical University.

Rostov-on-Don



A. M. Batiushina
Rostov State Medical University
Russian Federation

Alla M. Batiushina.

Rostov-on-Don



References

1. Yerigeri K, Kadatane S, Mongan K, Boyer O, Burke LLG, Sethi SK, et al. Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management. J Multidiscip Healthc. 2023;16:2233-2249. DOI: 10.2147/JMDH.S245620

2. Козловская Н.Л., Коротчаева Ю.В., Демьянова К.А., Шифман Е.М. Сравнительная характеристика акушерского и «общепопуляционного» атипичного гемолитико-уремического синдрома у взрослых. Нефрология и диализ. 2022;24(1):52-61. DOI: 10.28996/2618-9801-2022-1-52-61

3. Козловская Н.Л. Атипичный гемолитико-уремический синдром: современные представления о патогенезе, клинике, подходах к диагностике и лечению. Тромбоз, гемостаз и реология. 2019;4(8):13-20. DOI: 10.25555/THR.2019.4.0895

4. Tiwari V, Bhandari G, Gupta A, Gupta P, Bhargava V, Malik M, et al. Atypical HUS Triggered by COVID-19: A Case Report. Indian J Nephrol. 2022;32(4):367-370. DOI: 10.4103/ijn.ijn_196_21

5. Manickam N, Agrawal V, Prasad P, Jain M, Prasad N. Clinico-Histological Features of Thrombotic Microangiopathy in Renal Biopsies: A Retrospective Study. Turk Patoloji Derg. 2022;38(1):1-8. DOI: 10.5146/tjpath.2021.01536

6. Garcia-Arellano G, Camacho-Ortiz A, Moreno-Arquieta IA, Cardenas-de la Garza JA, Rubio-Torres DC, Garza-Gonzalez E, et al. Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19. Am J Med Sci. 2023;365(2):215-217. DOI: 10.1016/j.amjms.2022.10.012

7. de Groot PG, Meijers JC. β(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost. 2011;9(7):1275-84. DOI: 10.1111/j.1538-7836.2011.04327.x

8. Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828-2839. DOI: 10.1111/jth.15047

9. Gazzaruso C, Mariani G, Ravetto C, Malinverni L, Tondelli E, Cerrone M, et al. Lupus anticoagulant and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. 2021;52(1):85-91. DOI: 10.1007/s11239-020-02335-w

10. Chua JS, Zandbergen M, Wolterbeek R, Baelde HJ, van Es LA, de Fijter JW, et al. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. Mod Pathol. 2019;32(8):1147-1157. DOI: 10.1038/s41379-019-0259-z

11. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539-551. DOI: 10.1016/j.kint.2016.10.005

12. Prodinger WM, Hellwage J, Spruth M, Dierich MP, Zipfel PF. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J. 1998;331 ( Pt 1)(Pt 1):41-7. DOI: 10.1042/bj3310041

13. Józsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol. 2007;44(10):2697-706. DOI: 10.1016/j.molimm.2006.12.001

14. Zhang MF, Huang J, Zhang YM, Qu Z, Wang X, Wang F, et al. Complement activation products in the circulation and urine of primary membranous nephropathy. BMC Nephrol. 2019;20(1):313. DOI: 10.1186/s12882-019-1509-5

15. Saleem M, Shaikh S, Hu Z, Pozzi N, Java A. Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature. Front Immunol. 2022;13:909503. DOI: 10.3389/fimmu.2022.909503

16. Gao S, Cui Z, Zhao MH. Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy. J Am Soc Nephrol. 2022;33(9):1742-1756. DOI: 10.1681/ASN.2021101384


Supplementary files

Review

For citations:


Batiushin M.M., Beloborodova T.P., Korobka V.L., Nesterenko I.N., Sinelnik E.A., Bronovitskaya N.A., Bondarenko N.B., Batiushina A.M. A case of development of membranous nephropathy against the background of atypical hemolytic-uremic syndrome activated as a result of acute respiratory viral infection. South Russian Journal of Therapeutic Practice. 2023;4(4):101-106. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-4-101-106

Views: 458


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2712-8156 (Print)